A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- Coronavirus-Neutralizing Antibodies Detected in Japan for 1st Time
July 15, 2020
- Japan Govt to Tweak Honebuto Text for Off-Year Re-Pricing, but Still Holds to Original Plan
July 15, 2020
- LDP Lawmakers Irked as Govt Stands Fast on Off-Year Re-Pricing/Survey Plan; Honebuto Text Tweak Unclear
July 10, 2020
- MHLW’s OTC Panel Begins Discussions toward Interim Report; to Seek Solutions for Problems in Switch-OTC Approval
July 10, 2020
- Original Plan Remains Unchanged for Off-Year Drug Re-Pricing, Survey: Minister
July 9, 2020
- AnGes’ COVID-19 Vaccine Given Some Safety Confirmation Before Clinical Trial: MHLW Official
July 9, 2020
- LDP Lawmakers’ League to Launch Group to Protect People against HPV
July 8, 2020
- MHLW Set to Approve Label Expansions for Kadcyla, Keytruda, Imfinzi and More
July 7, 2020
- Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
- Create Cross-Bureau Scheme at MHLW to Fuel Rx-to-OTC Switches: Regulatory Reform Panel
July 6, 2020
- MHLW Donates Nearly 200 Million Yen to GARDP to Combat Antimicrobial Resistance
July 6, 2020
- Key MOF Panel Passes on Typical Budget Recommendation amid COVID-19
July 3, 2020
- Ruling Parties Call for Careful Discussions on Off-Year Drug Re-Pricing
July 3, 2020
- MHLW to Report Approval Plan for Otsuka Pharmaceutical Factory’s Infusion Solution on July 15
July 3, 2020
- LDP Generic Study Group Urges Govt to Restructure Drug Supply Chain
July 1, 2020
- LDP Study Group Calls for Budgets to Accelerate Genome Analysis Project
July 1, 2020
- Specific Vaccine Negotiations with AstraZeneca about to Start: Minister
July 1, 2020
- Japan Approval for MSD’s 9-Valent HPV Vaccine Delayed into July
June 30, 2020
- Japan Approves Entresto, 4 Other Novartis Meds, Rybelsus, 1st Humira Biosimilar and More
June 30, 2020
- 418 Key Drug Candidates Listed by 36 Societies, Panel to Outline Stable Supply Measures at Next Meeting
June 29, 2020
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…